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ADM      Acinar-to-ductal metaplasia 
bp    base-pairs 
CEL/CEL    Carboxyl ester lipase/gene 
CELP      Carboxyl ester lipase pseudogene 
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MODY     Maturity-Onset Diabetes of the Young 
PDAC      Pancreatic ductal adenocarcinoma 
PRSS1      Cationic trypsinogen gene 
RT      Room temperature 
TGF-beta     Transforming growth factor beta 
VNTR      Variable number of tandem repeats 












Carboxyl ester lipase (CEL) is a digestive enzyme produced by the acinar cells of the pancreas. Two 
single-base deletion variants of the CEL gene cause a frameshift in the variable number of tandem 
repeats region located in the last exon. These CEL variants lead to a syndrome of pancreatic exocrine 
dysfunction and diabetes, known as Maturity-Onset Diabetes of the Young (CEL-MODY). 
To get new insight into the disease mechanisms of CEL-MODY, our research group has developed a 
novel CEL-MODY knock-in mouse model. The overall aim of this project was to characterize this 
model. More specifically, we wanted to study the effect of the CEL-MODY protein at an organ level, 
with regard to pancreatic exocrine and endocrine dysfunction.  
The CEL-MODY mice showed signs of pathological changes in the pancreas at 3 months of age, 
while severe, irreversible changes were observed at 6 months of age for both males and females. We 
observed exocrine atrophy, fibrosis and fatty infiltration, which are well known features of chronic 
pancreatitis (CP). Immunostaining indicated loss of Cel expression in atrophic exocrine tissue. We 
also detected signs of Cel protein aggregation, suggesting that CEL-MODY cause disease through 
the misfolding-dependent pathway of CP. No signs of diabetes were observed at 6 months of age, 
indicating that the islets of Langerhans remain functional in our mouse model, despite severe exocrine 
damage.  
In summary, we found that the CEL-MODY mice developed spontaneous CP, making this the first 
mutant lipase mouse model for CP. However, the mice did not present any signs of diabetes 





1.1 The pancreas 
The human pancreas is an organ located in the upper abdomen surrounded by other organs such as 
the stomach, small intestine, kidney and spleen. This gland consists of an exocrine and an endocrine 
part that have two major functions vital for food digestion and blood glucose regulation, respectively. 
The pancreas is divided into three main anatomical areas, the head, body and tail (Figure 1.1 A).  
 
 
Figure 1.1. Overview of the anatomical areas of the pancreas. A) The pancreas is divided into three anatomical areas, 
the head, body and tail, where the tail is more distal, and the head is proximal relative to the torso. The head lies next to 
the duodenum with a twisted structure. There is a duct throughout the whole pancreas that merges with the common bile 
duct in the head region of the pancreas, making the major duodenal papilla that leads into the duodenum. Within the 
pancreas, the main duct branches out into multiple smaller ducts. B) The acinar cells are arranged around smaller ducts 
in which they secrete digestive enzymes. Alpha and beta cells make up the major type of cells in the pancreatic islets that 




1.1.1 The exocrine pancreas 
About 90 % of the pancreas is made of exocrine tissue, including acinar and ductal cells (Pandiri, 
2014). The parenchyma of the pancreas has lobe structures where acinar cells make up branched 
grape-like structures called acini (Figure 1.1 B). Each acinus has a similar orientation of dipole acinar 
cells laying around a lumen with their apical part towards this lumen. All acini are connected to 
intralobular ducts that leads to larger interlobular ducts, which further merges with the main 
pancreatic duct (Longnecker, 2014). In addition, the common bile duct from the gallbladder merges 
with the pancreatic duct, supplementing bile salts to the duodenum. The ductal secretion is called 
pancreatic juice and consists of water, bicarbonate and digestive enzymes (Longnecker, 2014).  
The pancreas can produce 1-2 litres of pancreatic juice every day (Jun et al., 2016). Production and 
secretion of bicarbonate is stimulated by the hormone secretin. Bicarbonate has an important role in 
neutralizing the pH in the duodenum which allows digestive enzymes to function in an optimal 
environment (Afroze et al., 2013).  
In the acinar cells, inactive and partially active digestive enzymes are budding off from the Golgi 
network in vesicles called zymogen granules, before being secreted via exocytosis from the apical 
part of the cell and into the ductal lumen (Motta et al., 1997). The zymogen granules carry multiple 
types of digestive enzymes as listed in Table 1.1. Secretion of digestive enzymes are stimulated by 
several signalling molecules. The most common are cholecystokinin, a gastrointestinal hormone, and 
acetylcholine, a neurotransmitter that stimulates calcium mobilization leading to exocytosis of 




Table 1.1. The most common digestive enzymes secreted by the pancreas. 
Digestive enzyme Biological Function Reference 
Proteases Digest peptides  
Chymotrypsin (B, C) Endopeptidase, cleaves peptide 
bonds after aromatic amino acid 
residues. 
(Tomita et al., 1989, 
Batra et al., 2013) 
Carboxypeptidase (A, B) Exopeptidase, cleaves aromatic 
and basic amino acids from c-
terminus. 
(Laethem et al., 1996) 
Elastase Endopeptidase, cleaves peptide 
bonds after small uncharged amino 
acid residues. 
(Szabó et al., 2016) 
Trypsin Endopeptidase, cleaves peptide 
bonds after basic amino acid 
residues. 
(Scheele et al., 1981) 
Lipases Digest lipids  
Pancreatic triglyceride lipase Cleaves ester bonds at sn-1 and sn-
3 of triglycerides. 
(Lowe, 1997) 
Phospholipase A2 Cleaves sn-2 acyls ester bond of 
phospholipids. 
(Gudgeon et al., 1991) 
Pancreatic lipase related protein 2 Cleaves ester bonds of 
triglycerides, galacto- and 
phospholipids. 
(Eydoux et al., 2008) 
Carboxyl ester lipase (CEL) Cleaves ester bonds of 
triglycerides, phospholipids, 
vitamin ester, cholesterol ester and 
fatty acids of hydroxyl fatty acids. 
(Johansson et al., 2018) 
Amylase Digest carbohydrates  
Pancreatic alpha-amylase Hydrolyses starch and glycogen. (Brayer et al., 1995) 
Nucleases Digest nucleotides  





1.1.2 The endocrine pancreas 
Within the parenchymal lobes, distinct spherical groups of cells known as the islets of Langerhans 
are present (Figure 1.1 B). The islets comprise the endocrine pancreas, making up approximately 2 
% of the organ (Murakami and Fujita, 1992) and consists of alpha, beta, gamma, delta and epsilon 
cells. The insulin producing beta cells make up the largest portion of the islets (~60%), followed by 
glucagon producing alpha cells (~30%) and the remaining 10 % is divided between delta, gamma and 
9 
 
epsilon cells, producing somatostatin, pancreatic polypeptide and ghrelin, respectively (Ionescu-
Tirgoviste et al., 2015).  
Insulin and glucagon are the two hormones important for maintaining glucose homeostasis in the 
body. When blood glucose rises after a meal, the beta cells are stimulated to produce insulin. 
Intracellular calcium stimulates secretion of insulin granules out into the blood (Mann and Bellin, 
2016). Insulin migrates in the blood veins and binds to its responding receptors at different periphery 
tissues, such as the muscle, liver and fat, thereby stimulating glucose uptake. The secretion of insulin 
keeps the blood glucose from elevating too high (Mann and Bellin, 2016).  
In contrast to insulin, glucagon up-regulates the blood glucose levels. When blood glucose is too low, 
alpha cells are stimulated to secrete glucagon into the bloodstream. Glucagon initiates liver 
glycogenolysis and gluconeogenesis, raising blood glucose to avoid hypoglycemia (Jiang and Zhang, 
2003).  
 
1.2 Pancreatic diseases 
1.2.1 Diabetes mellitus 
Diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia 
(Kharroubi and Darwish, 2015). In 2014, 8.5 % of adults worldwide were diagnosed with diabetes 
(World Health Organization, 2016). The two most common types are Type 1 Diabetes (T1D), 
accounting for around 5-10 % of diabetes cases, and Type 2 Diabetes (T2D), accounting for about 90 
% of diabetes cases (Goyal and Jialal, 2020). Other forms of diabetes are gestational and monogenic 
diabetes. 
T1D is an autoimmune disease that leads to destruction of the insulin producing beta cells (Bluestone 
et al., 2010). This disease mostly develops before the age of 20 (Maahs et al., 2010). One of the 
predominant genetic risk factors involve beta cell genes encoding antigen presenting molecules, 
causing an immune response (Concannon et al., 2009). 
The hallmark for T2D is insulin resistance, i.e. that the insulin targeted cells do not respond efficiently 
to the hormone. Age of onset is typically after 40 years of age (American Diabetes Association, 2014). 
However, with lifestyle risk factors such as obesity, physical inactivity and energy-dense diet, an 
increasing number of younger people are diagnosed with T2D (Pulgaron and Delamater, 2014).  
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Gestational diabetes is defined as glucose intolerance with onset or first recognition during pregnancy 
(American Diabetes Association, 2014). Around 7 % of pregnant women get this form of diabetes, 
although for most of them, it disappears after giving birth.  
Monogenic diabetes is caused by mutations in a single gene. A prevalence study from Norway found 
that 1.1 % of all patients in the Norwegian Childhood Diabetes Registry had monogenic diabetes 
(Irgens et al., 2013). Monogenic diabetes can be further sub-categorized into Maturity-Onset Diabetes 
of the Young (MODY), neonatal diabetes, syndromic diabetes and mitochondrial diabetes (Molven 
and Njolstad, 2011). MODY is the most common type of monogenic diabetes, characterized by 
autosomal dominant inheritance with neither beta cell autoimmunity nor insulin resistance. It usually 
leads to diabetes before 25 years of age (Urakami, 2019). Due to a relatively early onset and no insulin 
resistance, in addition to no beta cell autoimmunity, MODY is often misdiagnosed as T1D and T2D, 
respectively (Kavvoura and Owen, 2019). Today, 14 subtypes of MODY have been discovered 
(Urakami, 2019). The most common forms are caused by mutations in the hepatocyte nuclear factor 
1, hepatocyte nuclear factor 4 and glucokinase. Mutations in the carboxyl ester lipase gene, causing 
MODY8 or CEL-MODY, are described in section 1.5.1. 
 
1.2.2 Pancreatitis  
Pancreatitis is defined as inflammation of the pancreas. It can either be acute, which has a sudden 
onset and short duration, or chronic, which develops gradually and results in irreversible organ 
damage (Banks et al., 2010). Pancreatitis is a complex disease with multiple risk factors where 
environment, anatomy and genetics play an important role (Hegyi et al., 2020). If not reversible, 
acute, recurrent acute and chronic pancreatitis form a disease continuum (Mayerle et al., 2019). 
Acute pancreatitis (AP) can be divided into three stages: mild, moderate and severe depending on the 
presence and recurrence over a period (>48 hours) of organ failure and local or systemic 
complications (Banks et al., 2013). The most common cause of AP is obstructive (e.g. gallstone) and 
alcohol related (Chatila et al., 2019). Obstructive AP leads to retention of pancreatic juice drainage, 
but can be cured with fasting and by removing the blockage (Banks et al., 2013). Alcohol abuse is 
believed to sensitise acinar cells for cholecystokinin, thereby increasing the secretion of digestive 
enzymes which can build up and cause premature activation (Wang et al., 2009). In addition, alcohol 
can disrupt calcium influx in the ducts, leading to calcification that partially obstructs drainage of 
pancreatic juice (Whitcomb, 2012). Retention of pancreatic juice can lead to inappropriate activation 
of digestive enzymes, causing autodigestion within the pancreas. If not reversed or if it recurs, AP 
can progress into chronic pancreatitis (CP). 
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CP is characterized by progressive parenchymal fibrosis, maldigestion, diabetes mellitus and pain 
(Etemad and Whitcomb, 2001). Progressive pancreatic inflammation and necrosis results in loss of 
both exocrine and endocrine tissue. Known risk factors for CP are classified into: toxic-metabolic; 
genetic; autoimmune; recurrent and severe acute pancreatitis; obstructive; and idiopathic (Pham and 
Forsmark, 2018). How genetics play a role in CP will be described further in section 1.3. 
 
1.2.3 Pancreatic cancer 
Pancreatic cancer has the seventh highest mortality rate of all cancer types worldwide and the fourth 
highest in the United States (Rawla et al., 2019, Siegel et al., 2019). It can arise from both the exocrine 
and endocrine part of the pancreas. However, over 90 % of pancreatic cancers are adenocarcinomas 
arising from the exocrine gland (Hidalgo et al., 2015). Pancreatic neuroendocrine cancer is less 
common (<5 %) (Rawla et al., 2019). Some risk factors for pancreatic cancer are smoking, diabetes, 
alcohol, genetics and pancreatitis (Dhar et al., 2015).  
Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumour with a duct-like phenotype (Orth 
et al., 2019). A progression model has been characterized by an initial transition from normal 
pancreatic acinar cells into duct-like cells, termed acinar-to-ductal metaplasia (ADM) (Chuvin et al., 
2017). ADM is induced by transforming growth factor beta (TGF-beta) signalling (Chuvin et al., 
2017), typically observed as a consequence of stress from pancreatic inflammation and organ injury 
in pancreatitis (Murtaugh and Keefe, 2015). Furthermore, pro-oncogenic mutations induces ADM to 
become pre-invasive precursor lesions termed pancreatic intraepithelial neoplasia (PanIN) (Orth et 
al., 2019). Eventually, a gradual accumulation of mutations in tumour suppressor genes causes the 
PanINs to become invasive PDAC (Orth et al., 2019, Rawla et al., 2019).  
 
1.3 Pathways of genetic risk in chronic pancreatitis  
Progression from recurrent AP into CP can be driven by genetic factors (Mayerle et al., 2019). CP 
patients can have a complex set of genetic alterations that interplay with each other as well as other 
risk factors such as alcohol (Whitcomb, 2012). Today, three pathological pathways are described in 




1.3.1 The trypsin-dependent pathway 
Trypsin plays a major pathological role in pancreatitis, by premature activation and driving the 
progression of disease through its ability to activate other digestive enzymes inside the pancreas 
(Mayerle et al., 2019). Certain autosomal dominantly inherited mutations in the cationic trypsinogen 
gene (PRSS1) causes hereditary pancreatitis (Mayerle et al., 2019). Gain-of-function mutations can 
increase PRSS1s ability to autoactivate prematurely before entering the duodenum (Hegyi and Sahin-
Tóth, 2017). 
Other genetic risk factors are variants of serine protease inhibitor Kazal type 1 (SPINK1) and 
chymotrypsin C (CTRC) (Muniraj et al., 2014). In general terms, they manage trypsin inhibition and 
trypsinogen degradation, respectively. Pancreatic secretory trypsin inhibitor (encoded by SPINK1) 
inhibits trypsin and is up-regulated during inflammation (Muniraj et al., 2014). Loss-of-function 
mutations in SPINK1 impairs this inhibition of active trypsin. Too high calcium levels or loss-of-
function mutations inhibit CTRCs degradation capacity of inactive trypsinogen (Muniraj et al., 2014).  
 
1.3.2 The misfolding-dependent pathway 
More recently, an alternative pathway to premature trypsin activation has been identified. In common 
for the genes involved is that they encode misfolding proteins that lead to protein aggregation, 
impaired secretion, increased endoplasmic reticulum (ER)-stress, and eventually apoptosis (Sahin-
Toth, 2017). The pathway is named the misfolding-dependent pathway of genetic risk in CP and 
certain mutations in the digestive enzymes such as PRSS1, carboxypeptidase A1 (CPA1) and 
carboxyl ester lipase (CEL) have shown to belong to this pathway (Whitcomb et al., 1996, Fjeld et 
al., 2015, Sahin-Toth, 2017). The role of CEL in CP is further described below. 
 
1.3.3 The ductal pathway 
The cystic fibrosis transmembrane conductance regulator (CFTR) stimulates duct cells to produce 
bicarbonate-rich fluid which contributes to flushing trypsin out of the pancreas (Muniraj et al., 2014), 
and mutation variants of the CFTR has shown to increase the risk of CP 4-fold (Mayerle et al., 2019). 
Furthermore, the calcium sensing receptor (CASR) regulates calcium influx in the duct cells. Alcohol 
and certain mutation variants of CASR leads to impaired function, causing calcification that may 




1.4 Carboxyl ester lipase 
Carboxyl ester lipase (CEL), also known as bile salt-stimulated lipase (Hernell and Olivecrona, 1974), 
or bile salt-dependent lipase (Abouakil and Lombardo, 1989), is a digestive enzyme (EC 3.1.1.13). 
CEL is mainly expressed by the pancreatic acinar cells and accounts for about 4 % of the protein 
content in the pancreatic juice (Lombardo et al., 1978). The enzyme is secreted as partially inactive 
before entering the duodenum. Here, CEL is stimulated by bile salts and can hydrolyse ester bonds 
in cholesterol esters, fat-soluble vitamins, tri-, di-, and monoacylglycerols and several fatty acid esters 
of hydroxyl fatty acids (Lombardo and Guy, 1980, Kolar et al., 2016). CEL is also expressed in 
lactating mammary glands and is secreted as a content of breast milk (Blackberg et al., 1985). During 
infancy, fat absorption is low, however, CEL from the breast milk helps infants compensate for the 
low endogenous fat absorption (Lindquist and Hernell, 2010). 
 
1.4.1 The human CEL locus 
The human CEL gene is located at chromosome 9q34.3 and is ~10 kb in size, consisting of 11 exons 
(Figure 1.2.) (Taylor et al., 1991). In the last exon, there is a variable number of tandem repeats 
(VNTR) region consisting of nearly identical segments of 33 bp (Higuchi et al., 2002). The number 
of repeats vary from 3-23 in humans, although several studies have shown that 16 repeats is the most 
common (Ræder et al., 2006, Torsvik et al., 2010, Dalva et al., 2017). About 11 kb downstream of 
the CEL gene, a CEL pseudogene (CELP) is located (Figure 1.2). Despite having a high sequence 
homology to CEL, CELP is missing exons 2-7 and it also includes a stop codon in the second exon 
(Lidberg et al., 1992, Madeyski et al., 1999). Due to the premature stop codon, CELP is not expected 
to be translated into a functional protein (Nilsson et al., 1993). 
 
 
Figure 1.2. The human CEL locus. In red, the 11 exons of CEL are shown spanning a sequence of about 10 kb. Further 
downstream, the CEL pseudogene is shown in blue. Marked in grey are the CEL exons 2-7 missing in CELP. The 
remaining 5 exons of CELP are named 1’, 8’, 9’, 10’ and 11’ due to the sequence similarity with the corresponding exons 




1.4.2 The CEL protein 
The most common human CEL variant with 16 VNTR repeats has a predicted theoretical protein size 
of ~79 kDa (Johansson et al., 2011). However, CEL is a glycoprotein that is heavily modified in the 
C-terminal tail. Therefore, the fully modified protein is detected with a molecular weight up to 120 
kDa (El Jellas et al., 2018). The enzyme can structurally be divided into two parts, an N-terminal 
globular domain and an intrinsically disordered C-terminal domain (Figure 1.3). In the globular 
domain, there is an N-terminal ER-signalling sequence, a catalytic triad, multiple bile salt binding 
sites and a single site for N-glycosylation (Johansson et al., 2018). The C-terminal VNTR region is 
rich in proline (P), glutamic acid (E), serine (S) and threonine (T) residues, known as PEST-
sequences, which are recognised for rapid protein degradation (Rogers et al., 1986). However, the 
same threonine and serine residues are serving as O-glycosylation sites, and it has been suggested 
that O-glycosylation of the CEL VNTR has a protective role by masking the PEST sequence, thereby 
prohibiting degradation of the enzyme (Wang et al., 1995, Bruneau et al., 1997). 
 
 
Figure 1.3. Overview of the CEL protein structure. A presentation of the protein with its functional parts indicated by 
arrows. The catalytic function is driven by three amino acids making a catalytic triad in the active site. Binding of bile-
salts stimulates enzyme activation. O-glycosylation in the tail is believed to help with stability and secretion of the protein. 




1.4.3 From translation to secretion 
CEL follows the classical secretory pathway for digestive enzymes (Lombardo, 2001). The N-
terminal ER-signalling peptide of CEL translocates the protein into the ER, where it is cleaved off 
and the protein is further modified. In the ER, the chaperone glucose regulated protein 94 aids in 
folding and glycosylation of CEL (Bruneau and Lombardo, 1995). Then, N-glycosylation of Asn210 
occurs before CEL is transported to the Golgi network (Abouakil et al., 1993). Here, O-glycosylation 
occurs on the many serine and threonine residues of the VNTR region (Bruneau et al., 1997). 
Phosphorylation by casein kinase 2 on Thr340 is the final trigger for CEL to bud off from the Golgi, 
leaving the cell via exocytosis in zymogen granules (Pasqualini et al., 2000). 
 
1.5 Pathological variants of CEL 
1.5.1 CEL-MODY 
In 2006, Ræder et al. reported that mutations in the CEL VNTR cause an autosomal dominantly 
inherited syndrome of endocrine and exocrine dysfunction (Ræder et al., 2006). The mutations were 
discovered in two families from the Western Norway. Their pedigrees revealed a family history of 
early onset diabetes, characterized as MODY, and the syndrome was named CEL-MODY or 
MODY8.  
The CEL-MODY syndrome is caused by a single-base deletion in the first (DEL1) or fourth (DEL4) 
repeat of the VNTR. Both mutations lead to frameshifts, and the CEL-MODY variants encode 
truncated proteins due to a premature stop codon in the VNTR domain (Figure 1.4).  
 
Figure 1.4. Presentation of the 
CEL protein tail in two 
deletion variants. The REP 16 
is illustrating a wild-type CEL 
VNTR with 16 repeats, each 
repeat indicated in blue boxes. 
Both DEL1 and DEL4 show a 
truncated tail, where the 
deletion causes an alternate tail 
indicated in red boxes. Note 
that DEL1 has a stop codon in 
repeat 11 while DEL4 has in 
repeat 13. Figure modified 




CEL-MODY is a progressive disease with early exocrine dysfunction and lipomatosis (Ræder et al., 
2006, 2007). Diabetes develops in the 40s and multiple pancreatic cysts have been observed in the 
diabetic patients (Ræder et al., 2014). In addition, one patient developed PDAC at a later stage in life 
(A. Molven, pers. Comm). The patients were first diagnosed due to their diabetes development. 
However, exocrine dysfunction is believed to be preliminary to diabetes, as exocrine dysfunction is 
also observed in nondiabetic CEL-MODY patients (Tjora et al., 2013). Based on these findings and 
the cellular studies discussed below, CEL-MODY seems to move more towards the area of CP, with 
diabetes development as a secondary consequence. 
It is believed that the CEL-MODY syndrome is a gain-of-function disease where the mutant protein 
causes proteotoxic damage to the pancreas (Johansson et al., 2011, Torsvik et al., 2014, Xiao et al., 
2016). Supporting this hypothesis, an earlier study of a CEL knock-out mouse model showed no 
significant signs of pancreatic disease development, demonstrating that loss of CEL can be tolerated 
(Vesterhus et al., 2010). Compared to the normal CEL protein, the CEL-MODY protein results in 
misfolding, impaired secretion and formation of both intra- and extracellular aggregates (Johansson 
et al., 2011, Torsvik et al., 2014). The aggregates cause ER-stress and induces apoptosis (Xiao et al., 
2016). In addition, CEL-MODY proteins that have been secreted can be taken up again by adjacent 
cells and induce cell death (Torsvik et al., 2014, Dalva et al., 2020). The mutated protein has, in 
addition to a truncated tail, a totally different amino acid sequence in the tail region. This results in 
loss of multiple O-glycosylation sites and an increase in the local isoelectric point (pI) from 3.3 to 
11.8 and overall pI from 5.2 to 9.5 (Johansson et al., 2011). Moreover, the presence of multiple 
cysteines caused by the frameshift may result in disulphide bridges that prevent proper folding of the 
protein, making it prone to aggregation (Xiao et al., 2016).  
 
1.5.2 CEL-HYB 
In 2015, Fjeld et al. reported that a hybrid variant of CEL (CEL-HYB) was a genetic risk factor for 
CP (Fjeld et al., 2015). This CEL-HYB variant was observed with a 5-fold frequency in idiopathic CP 
cases compared to controls in German and French cohorts.  
CEL-HYB is most likely a result of nonallelic homologous recombination between CEL and CELP 
(Fjeld et al., 2015). The CEL-HYB allele is composed of exon 1-10 from CEL while exon 11 originates 
from CELP. The VNTR from CELP has a stop codon in repeat 3, which causes the CEL-HYB protein 
to be expressed with a truncated tail. When expressed in cell culture, CEL-HYB showed impaired 
secretion, intracellular retention, reduced enzymatic activity and induced cellular autophagy (Fjeld et 
al., 2015). Furthermore, there are unpublished data showing that CEL-HYB induces ER-stress, both 
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at the RNA and protein level (Tjora et.al., submitted). Based on these recent results, it is suggested 
that the CEL-HYB allele follows the misfolding-dependent pathway of genetic risk in CP (see section 
1.3.2).  
 
1.6 Mouse models for human disease 
In medical research, the mouse has been a popular animal model for many years due to its genetic 
and physiological similarity to humans (Perlman, 2016). The most common laboratory mice today 
originates from the house mouse (Mus musculus), which has been used to develop inbred strains 
(Phifer-Rixey and Nachman, 2015). Inbred strains are generated by breeding siblings to create 
isogenic (genetically identical) mice. On average, 20 generations of inbreeding are sufficient to 
produce a population of mice that are about 99 % homozygous (Beck et al., 2000). Currently, over 
400 inbred mice strains are available with one of the most popular being the C57BL/6 (Black 6) 
mouse (Benavides et al., 2019).  
When the aim is to reproduce a human disease in mice, the strengths and weaknesses of a mouse 
strain needs to be thoroughly evaluated (Saloman et al., 2019). For instance, the Black-6 strain has 
substrains such as the C57BL/6J and C57BL/6N. In both substrains, multiple single nuclear 
polymorphisms have been identified that causes phenotypical differences (Simon et al., 2013). 
Knowing these differences are therefore very important when choosing a suitable strain for analysing 
human disease mechanisms and avoids the risk of interfering phenotypes. However, one of the 
advantages of using inbred strains is that the mice all have a uniform phenotype due to the isogenic 
background of the strain. 
 
1.6.1 Genetically engineered mice 
Developing genetically engineered mice based on human genetic diseases can serve as a good model 
to investigate the pathogenic mechanisms (Gurumurthy and Lloyd, 2019). Genome engineering 
allows for specific and sustainable alterations by either inserting, deleting or replacing DNA 
sequences that can cause a loss-of-function or a gain-of-function phenotype (Housden et al., 2017). 
Genetically engineered mice with foreign DNA is termed transgenic mice (Kumar et al., 2009). 
Typically, deleting or modifying a DNA sequence to remove a gene is termed knock-out (KO), and 




1.6.2 Gene targeting by homologous recombination 
To generate a transgenic KI mouse, gene targeting by homologous recombination is a technique that 
involves introducing recombinant DNA into embryonic stem (ES) cells by stable transfection (Figure 
1.5 A) (Bouabe and Okkenhaug, 2013). A targeting vector is designed containing a selection marker 
for drug resistance and the recombinant DNA sequence of interest, flanked by sequences identical to 
the endogene sequence. These flanking sequences are termed homology arms (Ishii et al., 2014). In 
addition, the selection marker can be flanked by recombinase recognition sites for later deletion. The 
homology arms allow for homologous recombination, which is a natural process that can occur during 
meiosis or DNA repair where similar or identical DNA sequences are exchanged between two 
adjacent DNA strands (Gurumurthy and Lloyd, 2019). After homologous recombination, drug 
resistance allows for positive selection for the recombinant ES cells. A negative selection marker is 
included in the targeting vector, downstream of the homology arms, which can encode for toxic 
substance when homologous recombination has not occurred.  
Next, the recombinant ES cells are injected into a blastocyst and implanted into a pseudo pregnant 
female by in vitro fertilization (Figure 1.5 B) (Gurumurthy and Lloyd, 2019). As the recombinant ES 
cells and native ES cells in the blastocyst originates from different mouse strains, pups are born as 
chimeras with different coat colour. The chimeric pups can then be used for further breeding with Cre 
expressing mice (Figure 1.5 C). Cre is a recombinase that recognize the loxP sites and cuts out the 
positive selection marker (Gurumurthy and Lloyd, 2019). The next generation of pups will then be 





Figure 1.5. Overview of generating transgenic mice by gene targeting. A) A vector is transfected into ES cells 
by electroporation. The vector contains an exogenous sequence marked in red, flanked by homology arms 
indicated in blue boxes. Selection markers allow harvesting of targeted ES cells that have incorporated the 
exogene via homologous recombination. B) The targeted ES cells are then injected into a blastocyst also 
containing wild-type ES cells. Further, this blastocyst is implanted into a pseudo pregnant female that gives 
rise to chimeric pups. C) A chimera pup where the targeted ES cells have contributed to the germ layer is used 
to crossbreed with a cre-expressing mouse, performing excision of the positive selection marker in the 
exogenous sequence. The litters from this breeding are heterozygous for the exogene, indicated as 0/ki.  
 
1.6.3 Constructing CEL-MODY and CEL-16R transgenic mice 
Most research on CEL-MODY are based on cellular studies. To learn more about the disease 
mechanisms, our research group decided to develop a mouse model to be able to study CEL-MODY 
at the organ level. Previous mouse studies on CEL-MODY failed to show any pathological phenotype 
(Vesterhus et al., 2010, Ræder et al., 2013). However, neither of them used specific KI strategies for 
incorporating the human CEL-MODY VNTR into the endogenous mouse Cel locus. 
The principle behind generating the new CEL-MODY mouse model was to exchange the endogenous 
mouse Cel VNTR region with the human CEL-MODY VNTR. Thereby, expression is still regulated 
under the endogenous Cel promotor.  
Construction of the mouse model followed the techniques described above in section 1.6.2 and 
produced heterozygous CEL-MODY mice for human CEL-MODY VNTR (Figure 1.6). The CEL-




In addition to the CEL-MODY mouse, we developed a CEL-16R mouse strain. Here the mouse Cel 
VNTR region was exchanged with the human CEL VNTR with 16 VNTR repeats. The purpose of 
this strain was to serve as a control for the normal human CEL protein. Since the mouse Cel gene 
harbours only 3 VNTR repeats (Holmes and Cox, 2011), the CEL-16R mouse will help us to separate 
any potential phenotypic effect that might originate from changing the mouse Cel VNTR per se from 




Figure 1.6. The CEL-MODY and CEL-16R humanized knock-in locus. After gene targeting, generation of 
chimera and crossbreeding, two transgenic models were produced harbouring the human CEL-MODY VNTR 
and CEL-16R VNTR in exon 11, indicated by the red lines. One loxP site is left after Cre excision, indicated 




2 Aims of the study 
The overall objective of this study was to learn more about the disease mechanisms of CEL-MODY 
by characterizing the phenotype of a new CEL-MODY mouse model.  
The specific aims were: 
• To determine whether expression of CEL-MODY causes chronic pancreatitis in mice 
• If so, to determine whether CEL-MODY induced chronic pancreatitis causes subsequent 






Table 3.1. Genotyping 
Material Catalogue number Supplier 
E.Z.D.A DNA tissue DNA kit D3396-01 Omega Bio-Tek 
Multiplex PCR Kit 206143 Qiagen 
Tris-Borate-EDTA Buffer x10 A3945 PanReac, AppliChem 
SeaKem LE Agarose 50004 Lonza 
Ethidium Bromide (0.625 mg/ml) E406-15ml VWR 
Gel Loading Buffer G2526-5ML Sigma Aldrich 
100 bp DNA Ladder N3231 New England Biolabs 
 
 
Table 3.2. Pancreatic tissue lysis, SDS-PAGE and Western blot 
Material Catalogue number Supplier 
Trident RIPA lysis buffer GTX400005 Gene Tex 
cOmplete Protease Inhibitor Cocktail 11 697 498 001 Roche 
Pierce BCA Protein Assay Kit 23225 Thermo Scientific 
Phosphate-buffered saline 18912-014 Gibco 
Tween 20 P9416 Sigma-Aldrich 
NuPAGE LDS Sample Buffer (4x) NP0008 Invitrogen 
NuPAGE Sample Reducing Agent (10x) NP0009 Invitrogen 
NuPAGE 10% Bis-Tris Protein Gels, 1.0 mm, 10 well NP0301BOX Invitrogen 
MagicMark XP Western Protein Standard LC5602 Invitrogen 
Precision Plus Protein Dual Color Standard 1610374 Bio-Rad 
NuPAGE MOPS SDS Running Buffer (20X) NP0001 Invitrogen 
Blotting-Grade Blocker 1706404 Bio-Rad 
Amersham Hybond P Western blotting membranes, 
PVDF 
10600029 GE Healthcare 
Methanol 67-56-1 Merck Millipore 





Table 3.3. CEL-immunostaining and trichrome staining 
Materials Catalogue number Supplier 
Dako Pen S2002 Agilent Dako 
SuperFrost Plus™ Adhesion slides 10149870 Thermo Scientific™ 
Target Retrieval Solution, pH 9.0, 10x S2367 Agilent Dako 
Protein block, Serum-free X0909 Agilent Dako 
Antibody Diluent, Background Reducing S3022 Agilent Dako 
Liquid DAB+ Substrate Chromogen System K3468 Agilent Dako 
Hematoxylin S2020 Agilent Dako 
Pertex Mounting Medium 00811-EX Histolab 
Ventana trichrome staining kit 860-031 Roche 
 
 




Anti-CEL (rabbit polyclonal) Gift Gift from prof. Mark Lowe, 
Washington University School 
of Medicine, St. Louis, MO 
Primary (WB) 
Anti-β-actin (mouse monoclonal) sc-47778 Santa Cruz Biotechnology Primary (WB) 
Anti-CEL (rabbit polyclonal) HPA052701 Sigma Aldrich Primary (IHC) 
Goat anti-Rabbit IgG (H+L), HRP 656120 Invitrogen Secondary 
(WB) 
Donkey anti-mouse IgG-HRP sc-2306 Santa Cruz Biotechnology Secondary 
(WB) 
MACH3 rabbit HRP-polymer 
detection kit 
M3R531 Biocare medical Secondary 
(IHC) 
WB = Western blot, IHC = Immunohistochemistry 
 
 
Table 3.5. Glucose homeostasis test 
Materials Catalogue number Supplier 
D -(+)-glucose G8270 Sigma-Aldrich 
Humulin NPH Insulin ATC nr. A10A C01 Lilly 
Freestyle Freedom Lite glucose meter  Abbot 




Table 3.6. Buffers and solutions 
Solutions Use Composition 
2 and 3 % agarose gel Gel electrophoresis 2 or 3 % w/v SeaKem® LE Agarose dissolved in 1x 
TBE buffer and 1 µg/ml EtBr 
Blotting buffer Western blotting 1x NuPAGE Transfer Buffer and 10 % v/v methanol 
PBS-T Western blotting and 
CEL-immunostaining 
Phosphate-buffered saline with 0,05 % v/v Tween 20  
Blocking buffer Western blotting 5% w/v Blotting-Grade Blocker in PBS-T 
Antibody diluent Western blotting 1% w/v Blotting-Grade Blocker in PBS-T 
Glucose, 20% IPGTT 20 % w/v D –(+)-glucose in physiological saline (3 
% w/v NaCl) water 





Table 3.7. Technical equipment 
Instruments Use Manufacturer 
Applied Biosystems Thermal Cycler 2720 Genotyping Thermo Fischer Scientific 
NanoDrop ND-1000 Genotyping Thermo Fischer Scientific 
Gel Doc EZ Imager Genotyping and Western 
blotting 
Bio-Rad 
Infinite® 200 PRO Western blotting Tecan 
Leica DM2000 LED Histology Leica Microsystems 
Eppendorf Centrifuge 5417C Genotyping and Western 
blotting 
Applied Biosystems 
Megafuge 1.0 R Blood sampling Heraeus Sepatech 
XCell SureLock Mini-Cell Electrophoresis System Western blotting Thermo Scientific 





Table 3.8. Analytical software 
Software Use Supplier 
Microsoft Excel Mouse body weight development, tissue weight 
and glucose homeostasis 
Microsoft Corporation 
GraphPad Prism  Mouse body weight development, tissue weight 
and glucose homeostasis 
GraphPad Software, Inc 
Leica Application Suite v2.0 CEL-immunostaining and trichrome staining Leica Microsystems 
Aperio ImageScope HE-staining Aperio Technologies 
 
 
Table 3.8. Analytical software 
Software Use Supplier 
Microsoft Excel Mouse body weight development, tissue weight 
and glucose homeostasis 
Microsoft Corporation 
Microsoft Power Point Editing of figures Microsoft Corporation 
GraphPad Prism  Mouse body weight development, tissue weight 
and glucose homeostasis 
GraphPad Software, Inc 
Leica Application Suite v2.0 CEL-immunostaining and trichrome staining Leica Microsystems 







The CEL-MODY and CEL-16R mouse strain were developed on a C57BL/6N background. For both 
strains, breeding was performed with CEL-MODY/CEL-16R heterozygote males and wild-type 
females at the Laboratory Animal Facility, Faculty of Medicine, University of Bergen. The mice 
followed a normal 12-hour day/night cycle and were fed normal chow diet. Both males and females 
were studied. The mice were divided into twelve cohorts determined by gender, age, strain and 
genotype (Table 4.1.). Each cohort had a minimum of 6 mice. 
 
Table 4.1. Overview of cohorts studied. 
Gender 3 months 6 months 
Male Control Control 
Male CEL-MODY CEL-MODY 
Male CEL-16R CEL-16R 
Female Control Control 
Female CEL-MODY CEL-MODY 




4.2 Study approval 
Both animal breeding and the plan for animal experiments were approved by Mattilsynet (Norwegian 





4.3.1 DNA extraction 
Tissue sampling by ear punches were done on two-week-old mice and used to identify the genotype. 
DNA was extracted from mouse tissue using the E.Z.N.A tissue DNA Kit according to the 
manufacturer’s protocol. One exception was for lysis buffer treatment which was efficient after one 
treatment instead of two. The DNA concentration was measured using NanoDrop ND-1000. 
 
4.3.2 Polymerase chain reaction (PCR) 
First, a general PCR was performed for both CEL-MODY and CEL-16R strains to detect 
heterozygosity of the mouse Cel locus. Next, specific PCRs were set up to validate the presence of 
exogene CEL-MODY or CEL-16R VNTRs. PCR primer sequences are listed in Table 4.2. The PCR 
reaction was performed in a total volume of 25 µl and included 30-50 ng DNA, 1x Qiagen multiplex 
mastermix, 5 µM forward primer and 5 µM reverse primer. PCR programs used are listed in Table 
4.3. and 4.4.  
 
Table 4.2. Primers used for PCR genotyping 
General PCR Primer sequence 
196271cre (fwd) 5’- GCA AAC TTC TTA TTT ATC CTC AAG CCT TGG -3’ 
196272cre (rev) 5’- GTT ATC GTC TTA GTG ATG TCC AGG TAG TTG C -3’ 
CEL-MODY specific PCR  
0017-TS/PNI (fwd) 5’- GCC AAA GAG ACA TGC AGT GAG AAG AGT ACC -3’ 
198280oth (rev) 5’- CGA ATG TCA CAG CCC AGA ACT TCA GG -3’ 
CEL-16R specific PCR  
0018-TS/PNI (fwd) 5’- CCA CCA TGA GTC CAA TGA TTG CAC C -3’ 






Table 4.3. PCR program for general genotyping 
Step Temperature Time Cycles 
Pre-heat 95°C 15 min - 
Denaturing 94°C 60 sec 35 
Annealing 65°C 90 sec 35 
Extension 72°C 90 sec 35 
Final extension 72°C 10 min - 
Hold 4°C ∞ - 
 
 
Table 4.4. PCR program for CEL-MODY and CEL-16R specific genotyping 
Step Temperature Time Cycles 
Pre-heat 95°C 15 min - 
Denaturing 94°C 30 sec 30 
Annealing 65°C 30 sec 30 
Extension 72°C 5 min 30 
Final extension 72°C 8 min - 
Hold 4°C ∞ - 
 
 
4.3.3 Agarose gel electrophoresis  
For verification of the PCR products, 12.5 µl of PCR product was added 7.5 µl gel loading buffer and 
loaded on a 2 or 3 % agarose gel with TBE buffer and EtBr (1 µg/mL). Samples were loaded next to 
a 100 bp size marker and run at 90 V for one hour. Visualization of bands was done under UV-light 
using a Bio Rad Gel Doc EZ Gel Imager. The expected band sizes are listed in Table 4.5.  
 
Table 4.5. Expected PCR product size after agarose gel electrophoresis.  
General PCR Expected band size 
Wild-type 303 bp 
Heterozygote 303 + 394 bp 
Specific PCR  
Wild-type No band 
CEL-MODY 256 bp 




4.4 SDS-PAGE and Western blotting 
4.4.1 Preparation of mouse pancreas tissue lysates 
Mice were sacrificed at seven-weeks and their pancreas harvested. The organ was immediately snap-
frozen on liquid nitrogen. A small fraction of the pancreas was cut off and immediately put in 500 µl 
ice cold Trident RIPA buffer pre-supplemented with cOmplete Protease Inhibitor Cocktail (8.33 mM 
EDTA) and stored on ice. For homogenization, a pestle was used to stroke the tissue 10 times. The 
samples were then put on a rotary wheel for 20 min at 4°C. Further, the sample was centrifuged for 
15 min at 13000 rpm at 4°C before separating the supernatant from the insoluble pellet. The 
supernatant fraction was further analysed as the pancreas lysate. 
 
4.4.2 Protein concentration 
The protein concentration of pancreas lysates was measured using Pierce BCA Protein Assay Kit 
according to manufacturer’s protocol. The pancreas lysates were diluted 1:5 to fit within the protein 




For preparation of samples, 10 µg of protein from pancreas lysate was incubated with 1x LDS Sample 
Buffer and 2x Sample Reducing Agent at 56°C for 15 min. The samples were loaded next to 4 µl 
Precision Plus Protein Dual Color Standard and 2 µl MagicMark XP Western Protein Standard onto 
a 10% Bis-Tris protein gel and separated by electrophoresis in a XCell SureLock Mini-Cell system. 
The gel was run in 1x MOPS buffer first at 90 V for 15 min, then 180 V until the migration front had 
run out of the gel.  
 
4.4.4 Western blotting 
The proteins were transferred from the SDS gel onto a PVDF-membrane. Prior to blotting, the 
hydrophobic membrane was prewetted in 100% methanol (1 min) to be compatible in aqueous 
solution, followed by a short rinse in distilled water (1 min). The blotting sandwich was made in 
XCell Blot Module system according to Invitrogen. Blotting was performed at 30 V for one hour. 
Next, the membrane was incubated in Blocking buffer for one hour at room temperature (RT). After 
blocking, the membrane was washed 3x5 min in PBS-T before incubation with primary antibodies 
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overnight at 4°C. The primary antibodies used were rabbit anti-CEL (1:10 000) and mouse anti-β-
actin (1:2000 or 1:1000). Washing 3x5 min in PBS-T was done after incubation. The membrane was 
further treated with secondary HRP-conjugated anti-rabbit (1:5000) and anti-mouse (1:5000) 
respectively for one hour in RT. After incubation, the membrane was washed 3x5 min in PBS-T. ECL 
Plus Western Blotting Substrate was used for 5 min at RT before the chemiluminescent signal was 
detected using Bio Rad Gel Doc EZ Gel Imager. 
 
4.5 Mouse body weight development 
Weighing of the mice starting at eight weeks of age and continued every second week until the 
experimental end point at 14 or 28 weeks. It was performed consistently at the same time in the end 
of the week.  
 
4.6 Mouse tissue and blood collection 
At the experimental end point, tissues and blood samples were harvested. All mice were sacrificed 
by CO2 euthanasia. Blood was collected post-mortem by cardiac puncture and incubated at RT for 30 
min before centrifugation at 3000 rpm and 4°C for 10 min. The blood serum was separated from the 
plasma and stored at -80°C. Pancreas, liver, epididymal and subcutaneous white adipose tissue, 
muscle and brown adipose tissue were harvested. The tissues (except muscle) were weighed before 
being divided in two parts: one part stored in 4 % formaldehyde for histology/IHC analysis and the 
other part stored in liquid nitrogen for potential protein analysis. In this project, we only analysed the 
pancreas. Other tissues and blood samples were not investigated. 
 
4.7 Histology of the mouse pancreas  
4.7.1 Tissue preparation and Hematoxylin and Eosin (HE)-staining 
After fixation in 4 % formaldehyde at RT overnight, mice pancreas specimens were embedded in 
paraffin and cut into 4-µm sections onto SuperFrost Plus Adhesion Slides, followed by incubation at 
56 °C overnight. Embedding, sectioning and standard HE-staining were performed by the histology 
laboratory at the Department of Pathology, Haukeland University Hospital. After staining, the slides 





The pancreas tissue slides were baked at 56°C for at least 5 min before deparaffinizing in 100% 
xylene (2x5 min), 100 % ethanol (2x2 min), 96 % ethanol (2x2 min), 80 % ethanol (2 min) and 
distilled water (1 min with shaking). Epitope retrieval was done at 120°C in Target Retrieval Solution 
(pH 9.0) for 1 min using a pressure cooker. After retrieval, the slides were cooled at RT for 5 min 
before further cooling in running tap water. Next, the tissue slides were washed 3x5 min in PBS-T, 
blocked using Protein block for 10 min at RT, and further washed 3x5 min in PBS-T. For primary 
antibody incubation, rabbit anti-CEL (1:200, Sigma) was used at 4°C overnight in a humidity 
chamber. After incubation with primary antibody, the slides were washed 3x5 min in PBS-T before 
blocking of the peroxidase activity with 3 % H2O2 for 10 min at RT. Further, the slides were rinsed 
in distilled water for 1 min before being washed in PBS-T 3x5 min.  
For detection with secondary antibody, tissues were incubated with MACH3 anti-rabbit probe for 20 
min at RT, washed 3x5 min in PBS-T, then incubated with MACH3 anti-rabbit polymer for 20 min 
at RT. After polymer incubation, the tissues were rinsed in water for 1 min and washed 3x5 min in 
PBS-T. Substrate development was done with Liquid DAB+ Substrate Chromogen System for 3 min 
at RT. The reaction was stopped by dipping the slides in water, first rinsing and then washing for 2 
min. Nucleus staining was done using Hematoxylin (Dako) for 10-20 min at RT before rinsing in 
running tap water for 2 min. The slides were then dehydrated 1 min in distilled water, 80 % ethanol, 
96 % ethanol, 100 % ethanol and 2x2 min xylene before mounting with cover slips using Peritex 
Mounting Medium. Tissue slides were analysed with Leica DM2000 LED and Leica Application 
Suite v2.0. All washing steps were performed with shaking. 
 
4.7.3 Trichrome staining 
Trichrome Staining Kit (Ventana) was used to detect fibrosis. All solutions in the kit were ready to 
use, however, incubation times were optimized as described below. Baking and re-hydration of the 
tissue slides were done as described under 4.7.2. Tissue slides were treated with Bouin’s solution at 
50°C for 32 min in a humidity chamber before washing 3x2 min in distilled water. Nucleus staining 
was done by mixing reagents Hematoxylin A and B (1:1). The solution was applied to the slides, 
incubated for 4 min at RT, followed by washing 3x2 min in distilled water. For cytoplasm staining, 
Trichrome Red was applied for 6 min at 37°C and washed 3x2 min in distilled water. Trichrome 
Mordant was applied to removed excess red staining from collagen for 16 min at 37°C and followed 
by immediate addition of Trichrome Blue for collagen staining for 16 min at same temperature with 
no washing between. After collagen staining, the slides were washed 3x2 min in distilled water. 
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Trichrome Clarifier was applied for 3 min in RT before immediate dehydration in 80 % ethanol, 96 
% ethanol and 100 % ethanol. The slides were then kept in xylene 2x2 min before mounting of cover 
slips using Pertex Mounting Medium. All slides were analysed as described in 4.7.2. Each washing 
step was performed with shaking. 
 
4.8 Glucose homeostasis tests 
4.8.1 Intraperitoneal glucose tolerance test (IPGTT) 
Mice were fasted overnight for 14 hours in new cages. The mice were weighted before measuring 
blood glucose at time 0. The blood glucose was measured from a small cut by a razor on the distal 
part of the tail. All mice were kept in separate cages during the test. The glucose (20 %) was injected 
intraperitoneally into the posterior-distal part of the abdomen. Injection volume correlated with body 
weight (10 µl per gram body weight). After injection, blood glucose was measured with FreeStyle 
Freedom Lite glucose meter from the cut in the tail at time intervals of 15, 30, 60, 90 and 120 minutes.  
 
4.8.2 Intraperitoneal insulin tolerance test (IPITT) 
Mice were fasted for three hours (07.00 to 10.00) in new cages. Experimental procedures such as 
glucose measurements and injections were performed as described in section 4.8.1. Insulin 
concentrations used were different for the respective cohorts and listed in Table 4.6.  
 
Table 4.6. Insulin concentration used for IPITT in each cohort. 
Gender Age Insulin concentration (U/kg) 
Male 6 months 1 
Male 3 months 0.75 
Female 6 months 0.75 




Results were plotted as individual data points using GraphPad Prism 8 with the mean and standard 
error of the mean indicated. Differences of mean between two cohorts were analysed by unpaired t-




In this study, we have analysed CEL-MODY mice and compared them to two control mice strains. 
One of the controls is the CEL-16R mouse model that express the normal human VNTR with 16 
repeats. For both CEL-MODY and CEL-16R, we used heterozygous (0/ki) mice. In addition, we 
included control (0/0) mice from the breeding schemes of both CEL-MODY and CEL-16R mice. 
These are wild-type C57BL/6N mice and referred to as controls throughout this study.  
 
5.1 Identification and verification of transgenic CEL mice 
5.1.1 Genotyping of CEL-16R and CEL-MODY mice 
Before starting our animal experiment, all mice were genotyped by a PCR assay. DNA was extracted 
from mouse tissue and used as template. For each mouse strain, the assay included two PCR reactions. 
First, a general PCR was performed to distinguish between heterozygous (0/ki) and control (0/0) 
mice. Next, a specific PCR was set up to amplify the exogenous VNTR region of either CEL-16R or 
CEL-MODY.  The PCR products from each reaction were analysed by agarose gel electrophoresis 
and a typical genotyping result is presented in Figure 5.1. In the general PCR, a product with the size 
of 303 bp was expected for the wild-type allele, while an additional product of 394 bp was expected 
if the mouse carried one humanized Cel allele (see Methods, Table 4.5).  
Genotyping results of four mice from each of the CEL-16R and CEL-MODY strains are presented in 
Figure 5.1. The results of the general PCR showed two bands in the agarose gel at around 300- and 
400 bp for two CEL-16R mice and three CEL-MODY mice thus suggesting that these mice were 
heterozygous (Figure 5.1 A). In the remaining three mice, only one band at 300 bp was detected 
indicating control mice.  
These genotyping results were verified by the specific PCR products showing one band at about 300 
bp for the same five mice with two bands from the general PCR (Figure 5.1 B). The expected PCR 
product from amplifying an exogenous VNTR part from the CEL-16R mice was 286 bp, while 256 





Figure 5.1. Genotyping results of CEL-16R and CEL-MODY mice. PCR products were separated on a 2 % 
agarose gel stained with EtBr. Lane 1-4 represents genotyping of the CEL-16R strain and lane 6-9 represents 
genotyping of the CEL-MODY strain. The wells were loaded with 12.5 µl PCR product next to a DNA standard 
(std). Lane 5 was empty. A) Results from the general PCR. In lane 1, 2 and 6, one band was observed at 300 
bp which showed that these are control (0/0) mice. Two bands were present at 300 and 400 bp in lane 3, 4 and 
7-9, suggesting heterozygous (0/ki) mice. B) Results from the specific PCR. In lane 1, 2 and 6, no bands were 
detected, verifying the controls in A. Lane 3, 4 and 7-9 showed one band at about 300 bp, indicating CEL-16R 




5.1.2 Detection of humanized Cel proteins in CEL-16R and CEL-MODY mice 
To verify that the humanized Cel alleles were transcribed and translated into mature proteins, the 
expression of CEL-16R and CEL-MODY proteins were analysed in seven-week old heterozygous 
mice. Twelve mice were selected, six from each gender and four from each genotype. After sacrificing 
the mice, pancreata were isolated for preparation of pancreatic lysates. The protein concentration was 
measured for the lysates and 20 µg protein was loaded and separated by SDS-PAGE and analysed by 
western blotting. 
The results are shown in Figure 5.2. In all samples, one band was detected just above 60 kDa, which 
is the expected size for wild-type mouse Cel protein (~66 kDa, Uniprot #Q64285). For CEL-16R 
mice, two additional bands were detected at 100 kDa and just below, suggesting humanized Cel with 
16 VNTR repeats in a modified and unmodified state (El Jellas et al., 2018). As for the CEL-MODY 
mice, a band was detected just below 80 kDa, indicating a smaller Cel protein relative to the 
humanized 16R Cel, suggesting the truncated CEL-MODY protein. In the pancreatic lysates from 
female mice, one additional weak band was detected below 60 kDa, most likely due to unspecific 
antibody binding as seen in all female mice samples. Anti-beta actin was used as a loading control. 
 
 
Figure 5.2. Expression of Cel protein variants in seven-week old mice. Pancreatic lysates from controls and 
heterozygous CEL-16R and CEL-MODY mice were analysed by SDS-PAGE and western blotting. Cel 
expression was detected in both male and female mice by using an antibody targeting the globular domain of 





5.2 Mouse body weight development 
All mice were weighed every other week to evaluate body weight development until the experimental 
end point at 3 or 6 months of age. For the mice with experimental end point at 6 months, both males 
and females followed a similar growth pattern for all three cohorts (Figure 5.3). However, male mice 
seemed to plateau after 24 weeks of age at around 34 g (Figure 5.3 A), whereas the female mice grew 
until the experimental end point, reaching a weight around 27-28 g (Figure 5.3 B). We found no 
statistically significant difference in body weight between the CEL-MODY, CEL-16R and control 
mice at 6 months. Male mice sacrificed at 3 months of age displayed a similar pattern (Appendix, 
Figure 1 A). However, female CEL-MODY and CEL-16R mice sacrificed at 3 months of age weighed 
significantly more than controls at experimental end point (Appendix, Figure 1 B). Large individual 
increases in body weight could be observed at certain ages. These increases later evened out with 
other mice during growth up to 14 weeks, indicating sporadic growth in certain mice. Furthermore, 
for all mouse strains, individual body weight seemed to vary within the strains, resulting in large error 
bars (e.g. standard error of the mean = ±1.624 g for CEL-MODY females at 6 months). This indicated 
that there were larger inter-individual variations rather than variations in the mean weight between 













Figure 5.3. Body weight during life span of 6 
months old CEL-MODY, CEL-16R and control 
mice. The body weight (g) is presented as the mean 
at each age point for (A) males and (B) females. 




5.3 Weight of mouse pancreas 
The pancreas weight of all mice was measured at the experimental end points (3 and 6 months) and 
plotted as percentage of body weight (Figure 5.4). For males at 3 months, the pancreas of the CEL-
16R mice weighted significantly more compared to both controls (P < 0.05) and CEL-MODY (P < 
0.001) mice (Figure 5.4 A). The same trend appeared after 6 months, however, the difference between 
CEL-16R and CEL-MODY were less prominent although still significantly different (P < 0.05). 
There were no significant differences in relative pancreas weight between the CEL-MODY and 
control mice. 
For the females at 3 months of age, the relative pancreas weight of CEL-16R mice was also 
significantly higher compared to both controls (P < 0.05) and CEL MODY (P < 0.01) mice (Figure 
5.4 B). This difference was not observed for the female mice at 6 months of age.  
Taken together, the pancreas of the CEL-16R mice weighted significantly more compared to controls 
and CEL-MODY mice at 3 months, while less so or not significant at 6 months. Interestingly, the 
relative pancreas weight for female CEL-16R mice were higher at 3 months compared to the 











Figure 5.4. Pancreas weight of 3 and 6 months 
old CEL-MODY, CEL-16R and control mice. The 
pancreas weight (expressed as percentage of body 
weight) of each mouse with mean (horizontal bar) 
are shown for each cohort at 3 and 6 months for 
(A) males and (B) females. Error bars represent 
standard error of the mean. Statistical significance 
is indicated as * (P < 0.05), ** (P < 0.01) and *** 
(P < 0.001). N=6-13. 
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5.4 Pancreas histology of the CEL-MODY mice 
To investigate if the CEL-MODY mice developed spontaneous chronic pancreatitis, we looked at the 
pancreas histology of 3 and 6 months old mice and compared them to CEL-16R and control mice. 
After sacrificing the animals, the pancreas was harvested and fixated for histological analysis. HE-
stained sections for all the cohorts were evaluated. We included both male and female mice with n=6-
9 in each cohort. For both control and CEL-16R mice, the pancreas showed normal lobular structures, 
and the morphology of both the exocrine and endocrine tissue appeared normal. However, several 
CEL-MODY mice showed signs of a pathological phenotype already at 3 months, which became 
more severe at 6 months for both genders. An overview of the number of CEL-MODY mice affected 
in each cohort is presented in Table 5.1.  
 
Table 5.1. Overview of observed histological changes in the pancreas of CEL-MODY mice. The pancreas 
phenotype was classified with no (normal), mild or severe pathological changes based upon the overall 
presence of pancreas atrophy and fat-infiltration, and their dominance over normal tissue in the pancreatic 
lobes. 
CEL-MODY cohort Phenotype n = 
3 months, male 1 severely pathological, 2 mildly pathological, 3 normal 6 
3 months, female 3 mildly pathological, 3 normal 6 
6 months, male 4 severely pathological, 2 mildly pathological 6 
6 months, female 6 severely pathological, 2 mildly pathological, 1 normal 9 
 
HE-stained pancreas sections of selected male mice are presented in Figure 5.5 and Figure 5.6. At 3 
months, one male CEL-MODY mouse showed signs of severe pathological phenotype in the pancreas 
(Figure 5.5). Here, we observed areas with major acinar tissue atrophy. Compared to control, we also 




Figure 5.5. Pancreas histology of 3 months old CEL-MODY, CEL-16R and control mice. HE-stained 
pancreatic sections of male mice. Note severe pancreas atrophy for the CEL-MODY mouse. Images with scale 
bars 1 mm (left panel) and 400 µm (right panel). 
 
At 6 months, all CEL-MODY mice, except one female mouse, showed a mild to strong pathological 
phenotype, driven by fat infiltration and acinar atrophy. In the pancreas of CEL-MODY mice, we 
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observed certain lobes that were heavily dominated by fat, whereas others appeared almost normal 
(Figure 5.6). Acinar atrophy was also observed, often surrounded by fat.  
 
 
Figure 5.6. Pancreas histology of 6 months old CEL-MODY, CEL-16R and control mice. HE-stained 
pancreatic sections of male mice. Note pancreas atrophy and fat infiltration for the CEL-MODY mouse. Images 




Taken together, some atrophy of acinar tissue was observed for the CEL-MODY mice already at 3 
months of age, and was present in most mice at 6 months. There was fat-infiltration both between 
(inter) and within (intra) the lobes. At 6 months, this fat-infiltration seemed to dominate certain areas 
of the pancreas for most CEL-MODY mice, observed for both genders. The combination of fat 
infiltration and atrophy suggested that most CEL-MODY mice eventually would develop exocrine 
dysfunction. 
 
5.5 Immunohistochemistry for Cel expression in the mouse pancreas 
Pancreatic tissue sections from CEL-MODY, CEL-16R and control mice were analysed by 
immunohistochemistry for detection of both endogenous mouse Cel and CEL-MODY/CEL-16R 
proteins. For 3 months old CEL-16R and control mice, Cel staining was observed in the acinar cells 
of the exocrine pancreas (Figure 5.7). Upon closer inspection, Cel staining was observed in small 
grain-like structures in the apical part of acinar cells, indicating zymogen granules filled with Cel 
proteins. Positive Cel staining was also observed in some ducts confirming that Cel is secreted as part 
of the pancreatic juice. The endocrine islets were Cel negative. For the CEL-MODY mice, however, 
Cel was unevenly expressed in the exocrine tissue (Figure 5.7). More specifically, Cel expression 
seemed to be lost in several acinar cells. In addition, areas with a smeared pattern of Cel staining was 
observed, indicating the Cel proteins were no longer contained within the zymogen granules. The 




Figure 5.7. Immunohistochemistry for Cel expression in 3 months old CEL-MODY, CEL-16R and control 
mice. Pancreatic sections from male mice were stained using an antibody targeting the globular domain of 
Cel. Note the uneven expression in CEL-MODY. Scale bars are 200 µm (left panel) and 50 µm (right panel). 
 
For the same CEL-MODY mouse, several areas with intensive Cel signals were observed as dark 
spots within the lumen of acini (Figure 5.8). These spots were observed in atrophic exocrine areas 





Figure 5.8. Potential Cel protein aggregates in CEL-MODY mice. A pancreas section from one 3-month-old 
male CEL-MODY mouse was immunostained for detection of Cel expression. Red stars indicate areas of 
potential Cel protein aggregates. Scale bars are 200 µm and 50 µm. 
 
Compared to 3 months old mice, a similar Cel expression pattern was observed for CEL-16R and 
control mice at 6 months of age (Figure 5.9). In contrast, for the CEL-MODY mice at 6 months of 
age, certain lobes appeared to have normal Cel expression, while other lobes showed decreased Cel 
expression, indicating sporadic loss of Cel expression in the exocrine pancreas. The loss of Cel 






Figure 5.9. Immunohistochemistry for Cel expression in 6 months old CEL-MODY, CEL-16R and control 
mice. Pancreatic sections from male mice were stained using an antibody targeting the globular domain of 
Cel. Note the uneven expression in one lobe in the CEL-MODY mouse. Scale bars are 200 µm (left panel) and 
50 µm (right panel). 
 
As described in section 5.4, fat infiltration of the pancreas became prominent at 6 months of age for 
most CEL-MODY mice. When performing immunostaining, we observed Cel positive staining 
between fat cells that most likely had replaced the acinar tissue (Figure 5.10). Upon closer inspection 
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of these areas, low intensity Cel staining was observed close to the nucleus of some fat cells, 
suggesting a previous presence of Cel expressing acinar cells. 
 
 
Figure 5.10. Identification of Cel proteins between infiltrating fat cells. A pancreas section from one 6-
month-old male CEL-MODY mouse was immunostained for detection of Cel expression. Red stars indicate 
areas of Cel positive staining between fat cells. Scale bars are 200 µm and 50 µm. 
 
5.6 Staining for fibrotic tissue in CEL-MODY mice 
Pancreatic fibrosis is a characteristic feature of CP. To investigate if the CEL-MODY mice had signs 
of fibrosis development, we performed trichrome staining on pancreatic sections from 3 and 6 months 
old male mice. CEL-16R and control mice were included in the experiment and the results are 
presented in Figures 5.11 and 5.12. With the Ventana trichrome staining procedure, collagen (and 
consequently connective tissue) is stained in blue, cytoplasm in red while hematoxylin stains the 
nucleus violet. Collagen is a protein which is overrepresented in fibrotic tissue. In a normal pancreas, 
ducts and blood vessels are surrounded by connective tissue, as evident in the CEL-16R and control 
mice (Figure 5.11 and Figure 5.12). For the CEL-MODY mice, however, we observed large areas of 
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pancreatic tissue that had severe scarring, indicated by wide-spread fibrosis. In some areas, hardly 
any normal exocrine tissue was left (Figure 5.11 and Figure 5.12).  
 
 
Figure 5.11. Trichrome staining of pancreatic tissues in 3 months old CEL-MODY, CEL-16R and control 
mice. Pancreas sections from male mice were stained. Connective tissue is stained blue. Note the widespread 
fibrosis in CEL-MODY. Scale bars are 200 µm (left panel) and 50 µm (right panel).  
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Figure 5.12. Trichrome staining of pancreatic tissues in 6 months old CEL-MODY, CEL-16R and control 
mice. Pancreas sections from male mice were stained. Connective tissue is stained blue. Note the widespread 
fibrosis in CEL-MODY. Scale bars are 200 µm (left panel) and 50 µm (right panel).  
 
When further analysing the CEL-MODY mice, we observed several small duct-like structures in areas 
with wide-spread fibrosis (Figure 5.13). These could be distinguished from normal ducts by being 
small in size and the absence of pancreatic juice. They also appeared in a large quantity, in areas with 
almost no normal acinar tissue. Furthermore, some of these duct-like structures appeared to fuse with 
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each other, increasing their size. The presence of these duct-like structures may suggest acinar-to-
ductal metaplasia (ADM). 
 
 
Figure 5.13. Potential acinar-to-ductal metaplasia detected in CEL-MODY mice. Pancreas section from one 
3-month-old male CEL-MODY mouse was stained with trichrome for detection of fibrosis. Red stars indicate 
fusing duct-like structures. Scale bars are 100 µm and 50 µm. 
 
Interestingly, when analysing the CEL-MODY mice for pancreas histology, most endocrine tissue 
seemed unaffected despite the damage to the exocrine tissue surrounding it. Also, when analysing 
CEL-MODY mice by trichrome staining, we observed intact islets surrounded by fat. However, some 
of these islets were observed in closer proximity to each other compared to what was observed in 
normal pancreatic tissue (Figure 5.14). In addition, in some CEL-MODY mice, the endocrine islets 




Figure 5.14. Pancreatic islets surrounded by fat and fibrosis in CEL-MODY mice. Pancreas section from 
one 6-month-old male CEL-MODY mouse was stained with trichrome for detection of fibrosis. Note the two 
narrow islets being surrounded by fat and fibrotic tissue. Scale bar is 100 µm. 
 
5.7 Glucose homeostasis tests in mice 
To investigate if the CEL-MODY mice were diabetic, we measurred their abilty to regulate blood 
glucose by performing an IPGTT. At 6 month of age, no differences were observed between CEL-
MODY, CEL-16R and control mice, for either males or females, indicating normal glucose tolerance 





Figure 5.15. Intraperitoneal glucose tolerance test for 6 months old mice. Time 0 represents blood glucose 
measurments before injection. CEL-MODY, CEL-16R and control mice are compared for (A) males and (B) 
females and represented by the mean for each strain. Error bars represent standard error of the mean. 
 
Furthermore, we also performed an IPITT for mice at 6 months of age (Figure 5.16). No statistical 
difference could be observed in insulin sensitivity between CEL-MODY and control mice, indicating 
normal insulin sensitivity. However, 60 minutes after insulin injection, the CEL-16R male mice 
showed a statistically significant increase (P < 0.05) in blood glucose compared to both CEL-MODY 
and control mice (Figure 5.16 A). Then, 90 and 120 minutes after injection, the CEL-16R mice were 
still significantly higher than the control mice (P < 0.01) but not higher than the CEL-MODY mice. 
For the CEL-16R female mice, similar pattern was observed (Figure 5.16 B).  
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When performing the IPITT on mice 3 months old mice, the blood glucose dropped too low, including 
some that went into a hypoglycemic shock. The mice were all saved by glucose injections, however, 
they were excluded from the study.  
 
 
Figure 5.16. Intraperitoneal insulin tolerance test for 6 months old mice. Time 0 represents blood glucose 
measurments before injection. CEL-MODY, CEL-16R and control mice are compared for (A) males and (B) 





In 2006, our research group was the first to describe the pathogenic mutations in CEL known as CEL-
MODY. Since then, both cellular and clinical studies have been performed to learn more about the 
underlying disease mechanisms. Currently, we believe that CEL-MODY is a protein misfolding 
disease. Cellular studies have shown that the human CEL-MODY protein forms both intra- and 
extracellular aggregates that causes proteotoxic damage, ER-stress and apoptosis (Johansson et al., 
2011, Torsvik et al., 2014, Xiao et al., 2016). Clinically, the CEL-MODY syndrome is characterized 
by early exocrine dysfunction, followed by diabetes (Ræder et al., 2006). However, patients with the 
CEL-MODY syndrome also fulfil the criteria for CP (M. Lowe, pers. comm). Actually, two new 
CEL-MODY families from the Czech Republic and Sweden developed signs of CP before the 
manifestation of endocrine insufficiency occurred (Unpublished; A. Molven, pers. comm). Thus, 
CEL-MODY might as well be regarded as a form of inherited CP rather than a monogenic form of 
diabetes. 
In this study, we aimed to take our CEL-MODY research to the next level: we wanted to investigate 
the effect of CEL-MODY protein aggregation at the organ level. This was done by characterizing the 
phenotype of a newly developed CEL-MODY mouse strain. We evaluated whether the mouse strain 
was able to recapitulate the human phenotype observed in persons carrying the CEL-MODY mutation 
by investigating both male and female mice at 3 and 6 months of age, using both the CEL-16R strain 
and wild-type mice as controls.  
 
6.1 The first mutant lipase mouse model for CP 
The search for genetic variants associated with CP has been extensive since the first PRSS1 mutation 
was discovered in 1996 (Whitcomb et al., 1996). For many years, most of the genetic variants 
characterized were linked to the trypsin-dependent pathway (Hegyi and Sahin-Tóth, 2017). 
Consequently, the trypsin-dependent pathway has dominated our way of thinking about the disease 
and mouse models have been constructed to understand the role of trypsin in CP (Geisz and Sahin-
Tóth, 2018, Troy and Maxim, 2018).  
In this master project, however, we describe the first mutant lipase mouse model for CP development. 
Interestingly, heterozygous CEL-MODY mice at both 3 and 6 months showed typical hallmarks for 
CP including pancreatic atrophy, fibrosis, potential ADMs and fatty-infiltration. Based on cellular 
studies by us and others (Johansson et al., 2011, Torsvik et al., 2014, Xiao et al., 2016) and the fact 
that we observed signs of Cel protein aggregates in the pancreas of CEL-MODY mice, we believe 
53 
 
that CEL-MODY is acting through the alternative misfolding-dependent pathway (Sahin-Toth, 2017). 
Similarly, Hegyi and Sahin-Tóth have shown that a human CPA1 mutation also results in protein 
misfolding and ER-stress in both cellular and mouse models (Hegyi and Sahin-Tóth, 2019). 
Furthermore, the CPA1 mutant mice developed progressive acinar cell atrophy, inflammation, 
fibrosis and ADM. These findings correlate well with what we observed for the CEL-MODY mouse. 
However, additional analyses are needed to confirm induced ER-stress as well as inflammation in our 
CEL-MODY model. 
 
6.2 The CEL-MODY mouse recapitulates many of the features of CEL-MODY 
patients 
When the two Norwegian CEL-MODY families were identified, they presented symptoms of low 
fecal elastase, steatorrhea and fatty infiltration, indicating exocrine dysfunction (Ræder et al., 2006, 
2007). In a follow-up study on these patients, reduced digestive enzyme levels and bicarbonate in the 
pancreatic juice was detected, confirming reduced exocrine function (Tjora et al., 2013). 
Unfortunately, we did not have the time to measure pancreatic exocrine function in our mice (see 
section 6.7). However, we observed reduced Cel expression in atrophic exocrine tissue of CEL-
MODY mice, suggesting that the degradation of the exocrine tissue reduces the overall expression of 
digestive enzymes during CP development. Interestingly, the relative pancreas weight of CEL-
MODY mice did not decrease significantly compared to control mice as one could expect with 
massive exocrine atrophy. However, the fatty infiltration may be compensating for the loss of acinar 
cells and thereby keeping the overall weight stable.  
Fatty infiltration of the pancreas was a prominent feature in the CEL-MODY mice. Even so, these 
mice were not obese (no statistical significance compared to controls), excluding that overweight was 
a contributing factor. This correlates with similar observations for CEL-MODY patients as they were 
not overweight and had fatty infiltration of the pancreas, also in young non-diabetic subjects (Ræder 
et al., 2007). For the patients, the fatty pancreas was speculated to play a role in diabetes development, 
which usually occurred in their 40s. We did not detect any signs of diabetes development in the CEL-
MODY mice. Even when there was hardly any exocrine tissue left, the islets were still present and 
somewhat enlarged in size. Similar observations were seen in a mouse model for CP driven by 
trypsinogen activation, where fatty infiltration became dominant in later stages of CP, but no 
endocrine dysfunction was detected (Geisz and Sahin-Tóth, 2018). For the CEL-MODY mice, 
prolonging the experimental end point to 9 or 12 months might be sufficient for diabetes to manifest. 
Alternatively, a high-fat diet (HFD) can be used for Black-6 mice to induce metabolic diseases 
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(Fisher-Wellman et al., 2016). Actually, symptoms of impaired glucose tolerance have been observed 
in these mice after only 1-3 days into HFD (Fisher-Wellman et al., 2016). Therefore, putting the CEL-
MODY mice on an HFD would be interesting - whether that would trigger diabetes development.  
 
6.3 Fat infiltration of the pancreas 
In human adults, fat infiltration of the pancreas is common and mostly considered a benign condition 
(Coulier, 2016). Age and visceral fat index correlate to the grade of fatty infiltration. In extreme cases, 
fat infiltration may lead to exocrine pancreatic dysfunction and is found associated with diseases such 
as diabetes, pancreatitis, cystic fibrosis and other metabolic syndromes (Coulier, 2016). The precise 
etiology is often indecisive although fatty infiltration is regularly observed as secondary phenotype 
in disease progression.  
As mentioned previously, fatty infiltration is part of the phenotype of pancreatitis patients, including 
CEL-MODY patients (Ræder et al., 2007, Majumder et al., 2017). Interestingly, we observed severe 
fatty infiltration of the pancreas in 6 months old male and female CEL-MODY mice. The fat content 
seemed to increase with age as the phenotype was less prominent in the 3 months old mice. However, 
the origin of these fat cells remains a mystery.  
One hypothesis is that the fat cells are recruited from the peripancreatic fat tissue. Another hypothesis 
could be transdifferentiation, that acinar cells have differentiated into adipose cells. Acinar cells are 
prone to differentiation by cellular reprogramming, as beta-cell regeneration from acinar cells are 
used in diabetes therapy research (Kim and Lee, 2016). Furthermore, inactivation of the transcription 
factor c-myc have shown to cause loss of acinar maturation, leading to decreased pancreas mass and 
transdifferentiation into adipocytes (Bonal et al., 2009). ADM is another differentiation process 
driven by growth factors (Liu et al., 2016) and is arguably seen in the CEL-MODY mouse (Figure 
5.13). Interestingly, we observed positive Cel staining between adipocytes in the CEL-MODY 
pancreas (Figure 5.10), which may suggest that transdifferentiation from acinar cells has occurred. 
However, it is not clear whether the staining is present within or outside these adipocytes. Further 
experiments (e.g. electron microscopy) should be done to differentiate whether the Cel proteins are 
within the adipocytes or Cel protein are diffusing between the adipocytes from acinar leakage of 
zymogen granules. Actually, our research group is planning to follow up on this and do cell lineage 




6.4 Cel expression during CP development in mice 
Together with other digestive enzymes, Cel is secreted from the apical part of acinar cells as part of 
the zymogen granules. In control mice, we observed normal Cel expression throughout the exocrine 
pancreas, and when inspected closely, small grain-like structures were observed indicating the 
zymogen granules (Figure 5.7 and 5.9). These zymogen granules were seen polarized from the 
nucleus of the acinar cells, indicating normal secreting acinar cells (El Jellas et al., 2018). In CEL-
MODY mice, certain pancreatic areas showed reduced Cel expression as the exocrine tissue became 
more atrophic. A similar pattern is seen in pancreatic cancer where CEL expression is lost during 
ADM (El Jellas et al., 2018). Although abnormal exocrine tissue and Cel expression were seen in the 
CEL-MODY mice, some areas were normal, similar to control mice, indicating sporadic origin of 
pathogenesis in the CEL-MODY pancreas.  
Furthermore, we observed some patchy staining in the CEL-MODY mouse that could potentially 
indicate protein aggregation (Figure 5.8). However, it is not possible to determine if these proteins 
are present within the acinar cells or secreted into the acinus lumen. Previous cell culture studies have 
shown that the CEL-MODY protein form insoluble oligomers in both lysate and pellet fractions when 
analysed by western blotting, and protein aggregates were observed both intra- and extracellularly 
when analysed by electron microscopy and immunofluorescence (Johansson et al., 2011, Torsvik et 
al., 2014). Thus, we believe that these CEL-MODY aggregates also are present in the CEL-MODY 
mice and that they are the origin of pathogenesis for CP development. However, further investigation 
(e.g. electron microscopy) of the CEL-MODY mouse pancreas will provide more insight into the 
presence and location of these protein aggregates. 
 
6.5 Disease progression in CEL-MODY mice 
In secretory cells, protein misfolding in the ER activates the unfolded protein response (UPR) in an 
attempt to maintain cell viability and function (Hetz, 2012). CEL-MODY protein misfolding has also 
shown to activate the UPR in cellular studies (Xiao et al., 2016). Consequentially, UPR induced ER-
stress with elevated expression of the binding immunoglobulin protein (BiP) and X-box binding 
protein 1 (XBP1) (Xiao et al., 2016). In addition, the human CPA1 mutation mouse model discussed 
in section 6.1 showed induced ER-stress detected by markers such as the C/EBP homologous protein 
(CHOP) and BiP (Hegyi and Sahin-Tóth, 2019). Induced ER-stress by protein misfolding is one of 
the hallmarks in genetic CP for digestive enzymes following the misfolding-dependent pathway 
(Sahin-Toth, 2017, Mayerle et al., 2019).  
56 
 
Irreversible ER-stress trigger cell death by apoptosis, which has shown to be activated by nuclear 
factor kappa-light-chain-enhancer of activated B-cells (NF-κB) in cellular studies on CEL-MODY 
(Xiao et al., 2016). There is a crosstalk between UPR induced ER-stress markers and NF-κB that 
links protein misfolding to apoptosis (Schmitz et al., 2018). Furthermore, the activation of NF-κB in 
acinar cells are thought to induce inflammation by production of inflammatory cytokines (Murtaugh 
and Keefe, 2015). These cytokines stimulate activation of macrophages, which we unfortunately did 
not have time to investigate in the CEL-MODY mouse pancreas (discussed in section 6.7). Notably, 
inflammation was observed for the human CPA1 mutated mouse model by immunohistochemistry 
for the membrane protein F4/80 on macrophages (Hegyi and Sahin-Tóth, 2019). 
Within the exocrine pancreas lies quiescent pancreatic stellate cells (PSCs), which are activated upon 
inflammation and starts producing extracellular matrix (ECM) proteins, promoting fibrosis (Hamada 
et al., 2015). One of these ECM proteins is type 1 collagen, which we stained for in the CEL-MODY 
mice. We observed long fibre-like structures indicating fibrosis development, which is one of the 
main hallmarks of CP (Etemad and Whitcomb, 2001, Hegyi and Sahin-Tóth, 2019). 
In addition to ECM proteins, PSCs secrete growth factors such as TGF-beta (Xue et al., 2018), known 
to initiate dedifferentiation in acinar cells to ductal-like cells (Liu et al., 2016). We observed tubular 
duct-like structures within fibrotic areas in the CEL-MODY mouse, suggesting that activated PSCs 
in these areas both induced fibrosis and ADM. However, immunostaining for specific ADM markers 
such as sox9 and cytokeratin 19 would give more compelling evidence (Hessmann et al., 2016, Hegyi 
and Sahin-Tóth, 2019). 
Human chronic pancreatitis often leads to extensive fibrosis. However, in a mouse model for trypsin 
associated CP, they observed early CP with dilated ducts and fibrosis before fatty infiltration 
dominated in late stage CP (Geisz and Sahin-Tóth, 2018). This disease progression might be similar 
to what happens in the CEL-MODY mouse, although CEL-MODY follows a trypsin-independent 
pathway.  
Based upon current literature and the results in this study, we suggest that the pathological progression 
in the CEL-MODY mouse starts by misfolding of the CEL-MODY protein. This leads to formation 
of protein aggregates that induce ER-stress, apoptosis and inflammation. Further, inflammation 
activates PSCs which induces fibrosis and ADM before fatty infiltration takes over in later stage of 
disease. Nevertheless, additional studies are needed to make a precise progression model. It is 
noteworthy to mention the sporadic pathological development observed when investigating the 
pancreas of the CEL-MODY mouse. The morphological changes do not happen uniformly throughout 
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the pancreas, as certain lobes seem to be more affected than others. Interestingly though, this is 
commonly seen in patients with CP as well (C. Verbeke, pers. comm). 
The presence of potential ADM in the CEL-MODY mouse is also interesting in terms of pancreatic 
cancer development. Invasive PDAC do mostly origin from ADM accumulating pre-invasive 
precursor lesions (Liu et al., 2016). As mentioned in the introduction part of this thesis (section 1.5.1), 
PDAC has been observed in one older member of a CEL-MODY family. Interestingly, over 90 % of 
all PDAC cases harbour a mutation in the oncogene KRAS (Orth et al., 2019). However, a KRAS 
mutation alone is not enough to trigger development of invasive PDAC (Liu et al., 2016). 
Crossbreeding the CEL-MODY mouse with a KRAS mouse strain would therefore be very interesting 
in order to investigate if the CEL-MODY protein aggregates could trigger invasive pancreatic cancer 
in KRAS mouse. 
 
6.6 The CEL-16R mouse 
Compared to human CEL, the mouse Cel gene harbour only three VNTR repeats and the amino acid 
composition differ from the human VNTR (Holmes and Cox, 2011). Therefore, a CEL-16R mouse 
model was designed as a control to exclude the possibility that the human CEL VNTR per se could 
cause any pathological phenotype in the mouse. Similar to the wild-type controls, no morphological 
changes were observed in the pancreas of the CEL-16R mice, suggesting that the mice were healthy. 
However, the relative pancreas weight of the CEL-16R mice were significantly higher than for both 
wild-type controls and CEL-MODY mice, with the exception of females at 6 months of age (Figure 
5.4). In addition, the CEL-16R mice showed decreased insulin sensitivity compared to both wild-type 
controls and CEL-MODY mice (Figure 5.16). Taken together, we observed some differences between 
the CEL-16R mice and the wild-type control mice. Thus, we need to characterize the CEL-16R mice 
in more detail to be more confident about their phenotype, and to decide if they can be used as true 
controls or not.  
 
6.7 The impact of Covid-19 on the master project 
Due to the Covid-19 global health crises, strict guidelines were provided by the Norwegian 
Government. This involved a temporary lockdown of all laboratory work at the University of Bergen 
and Haukeland University Hospital. The lockdown lasted 6 weeks and therefore, two experiments 
planned for this thesis, were discarded due to lack of time. One of these experiments was 
immunohistochemistry for F4/80, a marker for inflammation. The other experiment was to analyse 
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serum alpha amylase activity, which is a way of measuring pancreatic exocrine function (Madole et 
al., 2016). Upon pancreas damage and CP, there is leakage of digestive enzymes into the blood stream 





The CEL-MODY syndrome is characterized by early exocrine dysfunction and diabetes. Although 
the syndrome was discovered as a monogenic form of diabetes, new insight might suggest that the 
diabetes develops secondary to exocrine dysfunction and CP. Here, the overall objective was to 
investigate the phenotype of a new transgenic CEL-MODY mouse strain – to see whether mice and 
human develop the same characteristic features and to learn more about the underlying mechanisms. 
We found that the CEL-MODY mouse developed acinar cell atrophy, fibrosis, potential ADM and 
fatty infiltration in the pancreas already at 3 months of age. These are well-known signs of CP - which 
became more severe at 6 months of age for both male and female CEL-MODY mice. We also 
observed potential Cel protein aggregates in the CEL-MODY pancreas, supporting that the mice 
develops disease through the misfolding-dependent pathway of CP. At 6 months of age, we did not 





8 Future perspectives 
With the CEL-MODY mice, we have developed a new animal model for CP. This gives us a range 
of possibilities for follow-up studies. However, to finish the first characterization study of the mice, 
we will focus on the experiments listed below.  
Perform 
• immunohistochemistry for the F4/80 marker in the pancreas of CEL-MODY mice to analyse 
the presence of inflammation 
• measure pancreatic alpha-amylase activity from blood serum collected from CEL-MODY 
mice to analyse pancreatic exocrine dysfunction 
• investigate up-regulation of ER-stress markers in acinar cells of CEL-MODY mice by western 
blotting 
• investigate the presence and location of protein aggregates in CEL-MODY mice by electron 
microscopy 
• perform immunohistochemistry for specific ADM markers in the pancreas to confirm its 
presence in CEL-MODY mice. 
• extend the experimental end point for CEL-MODY mice to 9- and 12 months to investigate 
whether they develop diabetes by IPGTT and IPITT 
• feed the CEL-MODY mice with an HFD to push them into glucose intolerance and to 
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Body weight development for mice at 3 months of age 
 
 
Figure 1. Body weight during life span of 3 months old CEL-MODY, CEL-16R and control mice. The body 
weight (g) is presented as the mean at each age point for (A) males and (B) females. Error bars represent 
standard error of the mean. Statistical significance is indicated as * (P < 0.05). N=6-13. 
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IPGTT for mice at 3 months of age 
 
 
Figure 2. Intraperitoneal glucose tolerance test for 3 months old mice. Time 0 represent blood glucose 
measurment before injection. CEL-MODY, CEL-16R and control mice are compared for (A) males and (B) 
females and represented with the mean for each strain. Error bar represent standard error of the mean. 
Statistical significance is indicated as * (P < 0.05) and ** (P < 0.01). 
